Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03094676
Other study ID # 57584116.6.0000.5402
Secondary ID
Status Recruiting
Phase N/A
First received February 21, 2017
Last updated March 8, 2018
Start date April 9, 2018
Est. completion date July 30, 2018

Study information

Verified date March 2018
Source Universidade Estadual Paulista Júlio de Mesquita Filho
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Performing physical exercise alters the body's homeostasis, and recuperative techniques seek to anticipate and potentiate the body's recovery. One of the ways to demonstrate a recovery of the organism is the resumption of autonomic cardiac modulation analyzed through heart rate variability (HRV), a method of global assessment of the behavior of the autonomic nervous system. Among the recovery techniques, massage is the most widely used technique in sports. Therefore, the objective of the study will be to measure the effects of massage as a recuperative technique on autonomic cardiac modulation at different moments of application. It will be a randomized clinical trial where there will be five stages of evaluation. In the first stage, the behavior of the baseline HRV will be evaluated, in the second stage the behavior of the HRV in front of the massage, in the third stage the behavior of the HRV in front of the stress protocol, in the fourth stage the HRV behavior after the stress protocol and immediately after Execution of the massage and finally in the 5th stage where the HRV behavior will be evaluated after the stress protocol and the massage application will be performed at the moment of HRV recovery. The stress protocol will be composed of squats followed by jumps and wingate test, and massage by slides in the anterior thighs and posterior trunk. The HRC indexes in the time domain, frequency domain and Poincaré plot, as well as cardiorespiratory parameters and a questionnaire on individual touch perception will be analyzed. The descriptive statistical method will be used and comparisons of cardiorespiratory parameters and HRV indices will be performed using the analysis of variance technique for repeated measures model in the two factor scheme. The level of significance will be p <0.05 for all tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 30, 2018
Est. primary completion date May 14, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Healthy Volunteers

- Appropriate age limit

- Male

Exclusion Criteria:

- Smokers

- Use of drugs that influence the autonomic modulation of the heart.

- Ethicalists

- Carriers of known metabolic and / or endocrine disorders

- Sedentary individuals, insufficiently active and very active according to IPAQ

- Individuals outside the BMI range

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Massage
Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
Exercise
A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.

Locations

Country Name City State
Brazil Nilton Mantovani Junior Presidente Prudente São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Universidade Estadual Paulista Júlio de Mesquita Filho

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Heart Rate Variability (HRV) - Linear indices - Frequency domain HRV is a noninvasive and selective way of assessing the autonomic function being determined by analyzing the time series of the RR intervals. The HRV analysis will be performed by the Polar Electro Oy - V800 cardiofrequency meter.
In the analysis of the linear methods, 3 rMSSD, SDNN and pNN50 indices will be used within the time domain. RMSSD corresponds to the square root of the square mean of the differences between the adjacent normal RR intervals in a time interval expressed in milliseconds. The SDNN index represents the standard deviation of all normal RR intervals recorded over a time interval, expressed in milliseconds. And finally, the pNN50 index is the percentage of adjacent RR intervals with a duration difference greater than 50 milliseconds.
First 5 minutes of rest; During recovery 5 minutes initial; 10º to 15ºm; 20º to 25ºm; 30º to 35ºm; 40º to 45ºm; 50º to 55ºm; 60º to 65ºm; 70º to 75ºm; 90º to 95ºm; 115º to 120ºm.
Primary Heart Rate Variability (HRV) - Linear indices - Time domain HRV is a noninvasive and selective way of assessing the autonomic function being determined by analyzing the time series of the RR intervals. The HRV analysis will be performed by the Polar Electro Oy - V800 cardiofrequency meter.
In the analysis of the linear methods, 3 LF, HF and LF / HF indices will be used within the frequency domain. Low frequency corresponds to frequencies between 0.04 and 0.15 Hz (LF - frequency between 0.04 and 0.15 Hz), high frequency (HF - frequency between 0.15 and 0.4 Hz) and the ratio between these components ( LF / HF). These indices shall be expressed in ms² and standard units.
First 5 minutes of rest; During recovery 5 minutes initial; 10º to 15ºm; 20º to 25ºm; 30º to 35ºm; 40º to 45ºm; 50º to 55ºm; 60º to 65ºm; 70º to 75ºm; 90º to 95ºm; 115º to 120ºm.
Primary Heart Rate Variability (HRV) - Plot of Poincaré HRV is a noninvasive and selective way of assessing the autonomic function being determined by analyzing the time series of the RR intervals. The HRV analysis will be performed by the Polar Electro Oy - V800 cardiofrequency meter.
The Poincaré plot is a map of points in Cartesian coordinates constructed from the values of the RR intervals obtained, where each point is represented on the x (horizontal / abscissa) axis by the preceding normal RR interval e, on the y axis (vertical / ordinate) By the following RR interval
First 5 minutes of rest; During recovery 5 minutes initial; 10º to 15ºm; 20º to 25ºm; 30º to 35ºm; 40º to 45ºm; 50º to 55ºm; 60º to 65ºm; 70º to 75ºm; 90º to 95ºm; 115º to 120ºm.
Secondary Heart rate. Heart rate is the number of heartbeats per unit of time. The heart rate will be measured by a heart monitor, and will be displayed in beats per minute (BPM). 1, 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 minutes.
Secondary Oxygen saturation. Oxygen saturation is the percentage of arterial blood hemoglobin that is bound to oxygen. Pulse oximetry will be used to gauge the oxygen saturation, pulse oximetry is the way to measure how much oxygen your blood is carrying. ... The oxygen level measured with a finger oximeter, and the result of this measurement is called the saturation level of oxygen (SatO2) 1, 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 minutes.
Secondary Respiratory rate. Respiratory rate is the designation given to the number of respiratory cycles that is completed in a specific time span, being more commonly expressed in breaths per minute. The respiratory rate will default to 1 minute to express the respiratory cycle number. The respiratory rate will be counted by an evaluator. 1, 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 minutes.
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1